Novel Immune Checkpoint Inhibitors in Advanced Cervix Cancer

David M. O’Malley, MD, provides insight on the evolution of cervical cancer and reviews current systemic treatment options for recurrent and advanced disease.

An expert gynecologic oncologist discusses the rationale for using PD-L1 inhibitors and CTLA4 inhibitors in gynecologic cancers.

Dr David M. O’Malley reviews ESMO 2021 updates evaluating the use of combination anti-PD-1 and anti-CTLA4 agents for recurrent and metastatic cervical cancer.

David M. O’Malley, MD, shares insight on data presented at SITC 2021 on the use of a second-generation, Fc-enhanced anti-CTLA4 antibody, AGEN1181, in patients with advanced cervical cancer as well as other solid tumors.

Dr David M. O’Malley comments on emerging agents in the pipeline for the treatment of recurrent/metastatic cervical cancer and shares his approach to the sequencing of therapies.

David M. O’Malley, MD, discusses the management of adverse events across various regimens for cervical cancer treatment and provides insight on future directions for disease management.